Crohn’s Disease Treatment Market

Crohn’s disease is a form of chronic inflammatory bowel disease (IBD) that causes inflammation in the gastrointestinal tract. This inflammation can take place anywhere between the ileum of the small intestine to the colon of the large intestine. Common symptoms of Crohn’s disease from mild to severe intensity include abdominal pain, reduced appetite, fever, and frequent diarrhea. Rectal bleeding is encountered in few cases due to fissures from inflammation at anal canal. Factors responsible for causing Crohn’s disease include hereditary genes, autoimmune reaction that causes inflammatory condition, and environmental factors such as bacteria and virus. The disease majorly affects people falling between age group of 15-35 years and occurs in both males and females.

There exists no specific cure for the disease, however various therapies can be employed on patients that can help to reduce signs and symptoms of the disease as well as can bring long-term remission. Improvement in long-term prognosis can be achieved through several medications prescribed for the treatment of Crohn’s disease that include anti-inflammatory drugs, immune system suppressers, antibiotics and other medication that helps to control inflammation.

Market Dynamics

The North America and Europe regions have high incidence of inflammatory bowel disease (IBD) such as Crohn’s disease, which is expected to drive growth of market. For instance, according to an article published in the journal Digestive Medicine Research in December 2020, in North America, the prevalence of IBD is projected to affect approximately 4 million persons by 2030. According to the same source, data from Canada reported a prevalence of IBD at 725 per 100,000 in 2018, which is estimated to rise to 981 by 2030. Thus the increasing prevalence of IBD is expected to drive market growth over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global crohn’s disease treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global crohn’s disease treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Takeda Pharmaceutical Company Limited, Mylan N.V., Amgen Inc., and AstraZeneca 
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global crohn’s disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global crohn’s disease treatment market

Detailed Segmentation:

• Global Crohn’s Disease Treatment Market, By Drug Type:
  • Antibiotics
  • Amino Salicylates
  • Corticosteroids
  • Immunomodulators
  • Others
• Global Crohn’s Disease Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
• Global Crohn’s Disease Treatment Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Janssen Biotech, Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Mylan N.V.
  • Amgen Inc.
  • AstraZeneca

 “*” marked represents similar segmentation in other categories in the respective section.